CORT Stock Analysis: Buy, Sell, or Hold?
CORT - Corcept Therapeutics Inc.
$85.90
-5.98 (-6.51%)
▼
5d:
-6.23%
30d:
+9.96%
90d:
+104.96%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 30, 2026
16d
Smart Money Accumulation
None View Scanner →
Strength: 4.6/10
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CORT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CORT shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$121.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$75.42
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $85.90, which is considered extended relative to its 30-day fair value range of $75.69 to $89.73. From a valuation perspective, the stock is trading at a discount (Forward PE: 36.8) compared to its historical average (41.2). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CORT is in a strong uptrend. The price is currently testing key support at $86.04. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CORT is in a strong uptrend. The price is currently testing key support at $86.04. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$75.69 -
$89.73
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
41.4%
Protect Your Profits
Holding CORT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- NEUTRAL: Near Wall St target ($88.00)
Trading Range Analysis
30-Day Trading Range
$75.69 -
$89.73
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$86.04
Resistance Level
$95.11
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
36.83
Wall Street Target
$88.00
(-4.2%)
Revenue Growth (YoY)
4.9%
Earnings Growth (YoY)
-21.6%
Profit Margin
6.2%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
36.8 vs 41.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$88.48
(-4%)
2-Year Target
$85.21
(-7%)
3-Year Target
$82.05
(-11%)
3-Yr Target (if PE normalizes)
(PE: 37→41)
$91.80
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 36.8, Growth: 411.8%)
$310.10
(+238%)
Base:
(SPY PE: 21.8, Growth: 411.8%)
$183.40
(+100%)
Bear:
(PE: 18.5, Growth: 411.8%)
$155.89
(+70%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (114x PE), but valuation improves significantly next year (37x PE) as earnings recover.
Forward PE: 113.64 | Forward EPS (Implied): $0.81
Bull Case
$110.95
(+21%)
Analyst growth 15.0%, PE expands to 119.3
Base Case
$91.88
(0%)
Market implied 0.0%, PE stable at 113.6
Bear Case
$70.29
(-24%)
Severe decline -15.0%, PE contracts to 102.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 36.8 to 41.2
Stabilization Target:
$102.79
(+11.9%)
PE Expansion Potential:
+11.9%
Share & Embed Analysis
Last updated: July 13, 2026 4:32 PM ET
Data refreshes hourly during market hours. Next update: 5:32 PM
Data refreshes hourly during market hours. Next update: 5:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
William Guyer
SELL
20000 shares
2026-04-07
Joseph K Belanoff
SELL
26198 shares
2026-03-25
William Guyer
SELL
11767 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
